1.3700
25-April-25 16:45:00
15 minutes delayed
Stocks
+0.0100
+0.74%
Today's range
1.3300 - 1.3900
ISIN
N/A
Source
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 Sep 2024 08:30:00 By Nasdaq GlobeNewswire